Thanks to everyone who is participating in this NEJM forum! I think it would be great for all our participants, readers and general well-wishers to begin by getting a sense of the needs assessment for idarucizumab.
In the paper, approximately 90/300 of the patients in the trial ended up having a bleeding event (cerebral, GI or otherwise). Does this number reflect the number of these exacerbations in the community? Are there certain patient populations that are at higher risk than others? Lastly, before idarucizumab, what was the morbidity and mortality linked to these bleeding episodes?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.